Generics in South Korea
August 2018
39
About the Report
About the Report
Generics in South Korea
Summary
Generics in South Korea industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Synopsis
Essential resource for top-line data and analysis covering the South Korea generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The South Korean generics market had total revenues of USD 4.8bn in 2017, representing a compound annual growth rate (CAGR) of 8.3% between 2013 and 2017.
- Market consumption volume increased with a CAGR of 3.3% between 2013 and 2017, to reach a total of 71% in 2017.
- Generics are becoming more and more popular in South Korea as the government realizes the cost saving potential.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in South Korea
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in South Korea
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the South Korea generics market with five year forecasts by both value and volume
Reasons to buy
- What was the size of the South Korea generics market by value in 2017?
- What will be the size of the South Korea generics market in 2022?
- What factors are affecting the strength of competition in the South Korea generics market?
- How has the market performed over the last five years?
- How large is South Korea's generics market in relation to its regional counterparts?
Products
Products
Generics, MarketLine, South Korea
Companies
Mylan N.V.
Novartis AG
Teva Pharmaceutical Industries Limited
Yuhan Corp
Table of Contents
Table of Contents
Table of Contents
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 9
Market value 9
Market volume 10
Market Segmentation 11
Geography segmentation 11
Market Outlook 12
Market value forecast 12
Market volume forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Mylan N.V. 20
Novartis AG 24
Teva Pharmaceutical Industries Limited 28
Yuhan Corp 31
Macroeconomic Indicators 34
Country data 34
Methodology 36
Industry associations 37
Related MarketLine research 37
Appendix 38
About MarketLine 38
List of Figure
List of Figures
Figure 1: South Korea generics market value: USD million, 2013-17
Figure 2: South Korea generics market volume: % of total pharma, 2013-17
Figure 3: South Korea generics market geography segmentation: % share, by value, 2017
Figure 4: South Korea generics market value forecast: USD million, 2017-22
Figure 5: South Korea generics market volume forecast: % of total pharma, 2017-22
Figure 6: Forces driving competition in the generics market in South Korea, 2017
Figure 7: Drivers of buyer power in the generics market in South Korea, 2017
Figure 8: Drivers of supplier power in the generics market in South Korea, 2017
Figure 9: Factors influencing the likelihood of new entrants in the generics market in South Korea, 2017
Figure 10: Factors influencing the threat of substitutes in the generics market in South Korea, 2017
Figure 11: Drivers of degree of rivalry in the generics market in South Korea, 2017
Figure 12: Mylan N.V.: revenues & profitability
Figure 13: Mylan N.V.: assets & liabilities
Figure 14: Novartis AG: revenues & profitability
Figure 15: Novartis AG: assets & liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities
Figure 18: Yuhan Corp: revenues & profitability
Figure 19: Yuhan Corp: assets & liabilities
List of Table
List of Tables
Table 1: South Korea generics market value: USD million, 2013-17
Table 2: South Korea generics market volume: % of total pharma, 2013-17
Table 3: South Korea generics market geography segmentation: USD million, 2017
Table 4: South Korea generics market value forecast: USD million, 2017-22
Table 5: South Korea generics market volume forecast: % of total pharma, 2017-22
Table 6: Mylan N.V.: key facts
Table 7: Mylan N.V.: key financials (USD )
Table 8: Mylan N.V.: key financial ratios
Table 9: Novartis AG: key facts
Table 10: Novartis AG: key financials (USD )
Table 11: Novartis AG: key financial ratios
Table 12: Teva Pharmaceutical Industries Limited: key facts
Table 13: Teva Pharmaceutical Industries Limited: key financials (USD )
Table 14: Teva Pharmaceutical Industries Limited: key financial ratios
Table 15: Yuhan Corp: key facts
Table 16: Yuhan Corp: key financials (USD )
Table 17: Yuhan Corp: key financials (KRW)
Table 18: Yuhan Corp: key financial ratios
Table 19: South Korea size of population (million), 2013-17
Table 20: South Korea gdp (constant 2005 prices, USD billion), 2013-17
Table 21: South Korea gdp (current prices, USD billion), 2013-17
Table 22: South Korea inflation, 2013-17
Table 23: South Korea consumer price index (absolute), 2013-17
Table 24: South Korea exchange rate, 2013-17
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.